Baxter International (BAX)
(Delayed Data from NYSE)
$36.91 USD
-1.06 (-2.79%)
Updated Oct 1, 2024 04:00 PM ET
Pre-Market: $36.91 0.00 (0.00%) 8:08 AM ET
2-Buy of 5 2
A Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$36.91 USD
-1.06 (-2.79%)
Updated Oct 1, 2024 04:00 PM ET
Pre-Market: $36.91 0.00 (0.00%) 8:08 AM ET
2-Buy of 5 2
A Value F Growth B Momentum C VGM
Zacks News
Stryker Gains From Flagship Mako and Broad Product Spectrum
by Zacks Equity Research
Stryker's (SYK) broad product spectrum cushions the company from any significant sales shortfall.
Abbott (ABT) Gets FDA Nod for New Troponin-I Blood Test
by Zacks Equity Research
The regulatory go-ahead for Abbott's (ABT) ARCHITECT STAT High Sensitivity Troponin-I blood test is a major stride forward in its commitment for detecting patients suspected of having a heart attack.
Haemonetics Grows on Strong Plasma, Hemostasis Management
by Zacks Equity Research
Haemonetics (HAE) is gaining traction from a steady progress in Plasma franchise.
Here's Why You Should Hold on to Wright Medical (WMGI) Stock
by Zacks Equity Research
Strong international footprint, solid prospects in the global orthopedic space and an enhanced product pipeline bode well for Wright Medical (WMGI). However, adverse forex mars prospects.
Illumina (ILMN) Gains on Product Pipeline, Global Footprint
by Zacks Equity Research
Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).
Medtronic's MiniMed 670G Shows Favorable Outcome in Europe
by Zacks Equity Research
Medtronic's (MDT) MiniMed 670G system boasts a special feature of SmartGuard Auto Mode that improves Time in Range.
Here's Why You Should Hold on to Nevro (NVRO) Stock for Now
by Zacks Equity Research
Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.
QIAGEN (QGEN) Hurt by Low QuantiFERON-TB Sales & FX Headwind
by Zacks Equity Research
Poor QuantiFERON-TB sales in Americas and an unfavourable currency translation affect QIAGEN's (QGEN) overall performance.
Fresenius Medical Launches 4008A Dialysis Machine in China
by Zacks Equity Research
Fresenius Medical (FMS) aims to treat ESRD patients in remote locations of China.
Align Technology Inks Distribution Deal With Zimmer Biomet
by Zacks Equity Research
This deal indicates Align Technology's (ALGN) commitment to strengthen its portfolio of iTero scanner and services.
PRA Health Simplifies Treatment Decisions With Metys Launch
by Zacks Equity Research
PRA Health (PRAH) expects to enhance position and capabilities in the data and analytics field with the new tool, while simplifying treatment decisions.
Tandem Diabetes Posts Positive Data on t:slim X2 With Basal-IQ
by Zacks Equity Research
Of late, Tandem Diabetes (TNDM) is investing in several developmental projects pertaining to the t:slim X2 insulin pump.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investor confidence continues to be high in Globus Medical (GMED), thanks to solid prospects.
Here's Why You Should Retain Pacific Biosciences For Now
by Zacks Equity Research
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, contraction in gross margin remains a woe.
Accuray's (ARAY) CyberKnife Delivers Improved Patient Outcome
by Zacks Equity Research
Accuray's (ARAY) CyberKnife delivers stereotactic body radiation therapy in only five sessions.
Zimmer Biomet's New JuggerStitch to Grow Sports Medicine Line
by Zacks Equity Research
Zimmer Biomet's (ZBH) JuggerStitch claims to offer a less invasive, all-suture, knotless approach to meniscal repair procedures.
Abbott Receives European Nod for Pediatric Heart Devices
by Zacks Equity Research
Abbott (ABT) aims to offer better treatment options for the most vulnerable patient population.
Intersect ENT Rides on Innovation Amid Pricing Concerns
by Zacks Equity Research
The SINUVA business line of Intersect ENT (XENT) makes a quick and remarkable progress with market access and field force balance.
HMS Holdings Acquires VitreosHealth, Boosts PHM Solution Set
by Zacks Equity Research
HMS Holdings (HMSY) can leverage VitreosHealth's prescriptive health insights that will enhance its growing and lucrative PHM suite.
Here's Why You Should Retain OPKO Health (OPK) Stock For Now
by Zacks Equity Research
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and solid R&D focus. However, operating losses remain a woe.
Varian's ProBeam Now Available in Multi-Room Configuration
by Zacks Equity Research
Shandong Cancer Hospital in China selects Varian (VAR) to equip its new research center with the ProBeam Proton Therapy system.
Medtronic Collaborates With Novo Nordisk for Diabetes Care
by Zacks Equity Research
This collaboration is expected to boost Medtronic's (MDT) diabetes management portfolio.
Zacks.com featured highlights include: Medtronic, Symantec, Target, Popular and Baxter International
by Zacks Equity Research
Zacks.com featured highlights include: Medtronic, Symantec, Target, Popular and Baxter International
Here's Why You Should Retain Patterson Companies (PDCO) Now
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from robust product portfolio, strong prospects in Animal Health unit and strategic buyouts. However, intense competition remains a woe.
Abbott's (ABT) FreeStyle Libre Gains Canadian Reimbursement
by Zacks Equity Research
With this reimbursement approval, Abbott's (ABT) FreeStyle Libre becomes the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada.